Acute Myeloid Leukemia with FLT3 Mutation

Acute Myeloid Leukemia with FLT3 Mutation — Trials · CancerIndex

Clinical trials

Registered studies

15 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 4
Recruiting: 3
Ph III recruiting: 0
Growth YoY: —
Industry share: 50%
Top sponsor: Shijiazhuang Yiling Pharmaceutical Co. Ltd
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (4)

clinicaltrialsPublishedShowing 1–1 of 1 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03735875	Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid Leukemia	terminated	Phase 1 / Phase 2	8	M.D. Anderson Cancer CenterOTHER	1	Sep 19, 2024	clinicaltrials

Data updated 23 days agoSource updated Sep 19, 2024source: clinicaltrials